Binding conformers searching method for ligands according to the structures of their receptors and its application to thrombin inhibitors

Acta Pharmacologica Sinica

Volumn 18, Issue 1, 1997, Pages 36-44

  Jiang, Hua Liang ^a   Chen, Kai Xian ^a   Tang, Yun ^a   Chen, Jian Zhong ^a   Li, Quan ^a   Wang, Qin Mi ^a   Ji, Ru Yun ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

ligands; molecular conformation; molecular mechanics; phosphonopeptides; structure activity relationship; thrombin receptor

Indexed keywords

PHOSPHONOPEPTIDE; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG CONFORMATION; ENERGY; LIGAND BINDING; PROTEIN STRUCTURE; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION; TECHNIQUE;

BINDING SITES; COMPUTERS; DRUG INTERACTIONS; LIGANDS; MOLECULAR CONFORMATION; ORGANOPHOSPHORUS COMPOUNDS; RECEPTORS, THROMBIN; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN;

EID: 0031034827     PISSN: 02539756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Colman PM. Structure-based drug design. Curr Opin Struct Biol 1994; 4: 868-74.
2. Kollman PA. Theory of macromolecule-ligand interactions. Curr Opin Struct Biol 1994; 4: 240-5.
3. BlaneyJM, Dixon JC. A good ligand is hard to find: automated docking methods. Persp Drug Discov Design 1993; 1: 301-19.
4. Lorand L, Konishi K. Activation of the fibrin-stabilizing factor of plasma by thrombin. Arch Biochem Biophys 1964; 105: 58-67.
5. Taparelli C, Metternich R, Ehrhardt C, Cook NS. Synthesis low-molecular weight thrombin inhibitors: molecular design and pharmacological profile. Trends Pharmacol Sci 1993; 141: 366-76.
6. Cheng L, Goodwin CA, Scully MF, Kakkar VV, Claeson G. Substrate-related phosphonopeptides, a new class of thrombin inhibitors. Tetrahedron Lett 1991; 49: 7333-6.
7. SYBYL [Computer programme]. Version 6.1. St Louis (MO): Tripos Associates, 1994.
8. SYBYL programming language (SPL). [Computer programming language for SYBYL software]. St Louis (MO): Tripos Associates, 1994.
9. Bode W, Mayr I, Baumann U, Huber R, Stone SR, Hfsteenge J. The refined 1.9 Å crystal structure of human α-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J 1989; 8: 3467-5.
10. Cramer RD III. Partial least squares (PLS) strengths and limitations. Presp Drug Discov Des 1993; 1: 269-78.
11. Marshall GR, Barry CD, Bosshard HE, Dammkoehler RA. Dunn DA. The conformational parameter in drug design. In: Olson EC, Christofersen RE, editors. The American Chemical Society Symposium; vol 112. Washington DC: American Chemical Society, 1979: 205-26.
12. Martin YC, Bures MG, Danaher EA, DeLazzer J, Lico I, Pavlik PA. A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepin agonists. J Comput-Aided Mol Des 1993; 7 (1): 83-102.
13. Brook III CL. Methodological advances in molecular dynamics simulations of biological systems. Curr Opin Struct Biol 1995; 5: 211-5.
14. Kollman PA. Free energy calculations: applications to chemical and biochemical phenomena. Chem Rev 1993; 93: 2395-417.